Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab with Chemoradiotherapy in Stage III NSCLC
NCT03631784Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2018
- Primary completion
- Oct 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
Phase 2, open-label trial of pembrolizumab in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by Merck & Co. Primary endpoints: Percentage of Participants Who Developed Grade 3 or Higher Pneumonitis up to 3 years and Overall Response Rate up to 3 years. Started Oct 2018; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03631784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03631784.